Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

Phase 1

Recruiting

Conditions: B Acute Lymphoblastic Leukemia
Recurrent Childhood Acute Lymphoblastic Leukemia
Philadelphia Chromosome Positive
Recurrent Adult Acute Lymphoblastic Leukemia
Minimal Residual Disease
Refractory Acute Lymphoblastic Leukemia
CD19 Positive

Interventions: Biological: Chimeric Antigen Receptor T-Cell Therapy
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Other: Questionnaire Administration

First Posted Date: 2017-08-08

Last Posted Date: 2024-07-11

Lead Sponsor: Crystal Mackall, MD

Target Recruit Count: 50

Registration Number: NCT03241940

Locations: 🇺🇸
Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States

Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer

Phase 1

Terminated

Conditions: HLA-A*0201 Positive Cells Present
Sarcoma
Unresectable Malignant Neoplasm
Locally Advanced Malignant Neoplasm
NY-ESO-1 Positive

Interventions: Other: 18F-FHBG
Biological: Aldesleukin
Drug: Busulfan
Biological: Cellular Therapy
Procedure: Computed Tomography
Biological: Filgrastim
Drug: Fludarabine
Procedure: Leukapheresis
Drug: Plerixafor
Procedure: Positron Emission Tomography

First Posted Date: 2017-08-07

Last Posted Date: 2023-11-01

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 5

Registration Number: NCT03240861

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

Phase 1

Active, not recruiting

Conditions: B Acute Lymphoblastic Leukemia
Minimal Residual Disease
CD19 Positive
Philadelphia Chromosome Positive

Interventions: Biological: Chimeric Antigen Receptor T-Cell Therapy
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Other: Questionnaire Administration
Drug: NKTR-255

First Posted Date: 2017-07-31

Last Posted Date: 2024-02-28

Lead Sponsor: Crystal Mackall, MD

Target Recruit Count: 56

Registration Number: NCT03233854

Locations: 🇺🇸
Stanford University, School of Medicine, Palo Alto, California, United States

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Squamous Cell Carcinoma
Adenosquamous Carcinoma
Advanced NSCLC
Adenocarcinomas
Metastatic Non-small Cell Lung Cancer
Non-Small Cell Lung Cancer

Interventions: Procedure: Tumor-infiltrating Lymphocytes (TIL)
Drug: Nivolumab
Drug: Cyclophosphamide
Drug: Fludarabine
Other: Tumor-infiltrating Lymphocyte Therapy
Drug: Interleukin-2 (IL2)

First Posted Date: 2017-07-12

Last Posted Date: 2023-07-24

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 20

Registration Number: NCT03215810

Locations: 🇺🇸
University of Florida Health Cancer Center., Gainesville, Florida, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Recruiting

Conditions: Recurrent Acute Myeloid Leukemia
High Risk Myelodysplastic Syndrome
Refractory Acute Myeloid Leukemia

Interventions: Drug: Cytarabine
Biological: Filgrastim
Drug: Fludarabine
Drug: Idarubicin
Biological: Pegfilgrastim
Drug: Venetoclax

First Posted Date: 2017-07-11

Last Posted Date: 2024-12-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 116

Registration Number: NCT03214562

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 2

Active, not recruiting

Conditions: Leukemia, Chronic Lymphatic
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphocytic Leukemia, Chronic, B Cell
Lymphocytic Leukemia, Chronic, B-Cell
B-Cell Chronic Lymphocytic Leukemia
B-Lymphocytic Leukemia, Chronic
Chronic Lymphocytic Leukemia
Leukemia, Chronic Lymphocytic, B-Cell
Leukemia, Lymphocytic, Chronic

Interventions: Drug: Ibrutinib
Drug: Fludarabine
Drug: Pembrolizumab

First Posted Date: 2017-06-29

Last Posted Date: 2023-11-28

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 15

Registration Number: NCT03204188

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Phase 1

Active, not recruiting

Conditions: Acute Myeloid Leukemia in Remission
Adult Acute Lymphoblastic Leukemia in Complete Remission
Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission
Chronic Myelomonocytic Leukemia in Remission
Graft Versus Host Disease
Severe Aplastic Anemia
Hodgkin Lymphoma
Minimal Residual Disease
Myeloproliferative Neoplasm
Non-Hodgkin Lymphoma

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Melphalan Hydrochloride
Drug: Mycophenolate Mofetil
Drug: Sirolimus
Radiation: Total-Body Irradiation

First Posted Date: 2017-06-20

Last Posted Date: 2024-05-29

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 35

Registration Number: NCT03192397

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Phase 1

Recruiting

Conditions: Pancreatic Cancer
Gastric Cancer
Colon Cancer
Rectal Cancer
Gastrointestinal Cancer

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Anti-KRAS G12V mTCR PBL
Drug: Aldesleukin

First Posted Date: 2017-06-19

Last Posted Date: 2024-12-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 110

Registration Number: NCT03190941

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors

Phase 1

Conditions: Advanced Malignant Solid Tumor

Interventions: Biological: Neoantigen Reactive T Cells(NRTs)
Biological: SHR-1210
Drug: Fludarabine
Drug: Cyclophosphamide
Biological: Interleukin-2

First Posted Date: 2017-05-31

Last Posted Date: 2017-06-06

Lead Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Target Recruit Count: 40

Registration Number: NCT03171220

Locations: 🇨🇳
The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, Jiangsu, China

Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major

Phase 4

Conditions: Thalassemia Major

Interventions: Drug: Busulfan
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Mycophenolate mofetil
Drug: Tacrolimus
Drug: Methotrexate
Drug: Thymoglobulin
Drug: Basiliximab

First Posted Date: 2017-05-31

Last Posted Date: 2017-05-31

Lead Sponsor: First Affiliated Hospital of Guangxi Medical University

Target Recruit Count: 30

Registration Number: NCT03171831

Locations: 🇨🇳
First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy